Introduction of a Composite Parameter to the Pharmacokinetics of Venlafaxine and its Active O‐Desmethyl Metabolite

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Journal of clinical pharmacology

• Publication date

  1992-08-01

• Fields of study

  Medicine, Computer Science

• Identifiers
  DOI 10.1002/j.1552-4604.1992.tb03875.xPMID 1487561
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antidepressants

  2012cited by this paper
• Biochemical, neurophysiological, and behavioral effects of Wy‐45,233 and other identified metabolites of the antidepressant venlafaxine

  1991cited by this paper
• What are "cyclic" antidepressants?

  1990cited by this paper
• Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate.

  1989cited by this paper
• Relationships between steady-state and single-dose plasma drug concentrations for pharmacokinetic systems with nonlinear elimination.

  1989cited by this paper
• Kinetics of drug action in disease states. XXIV. Pharmacodynamics of diazepam and its active metabolites in rats.

  1988cited by this paper
• An open-label, dose-finding study of WY-45,030, a novel bicyclic antidepressant.

  1988cited by this paper
• Psychopharmacology: The third generation of progress

  1988cited by this paper
• An open-label, variable-dose study of WY-45,030 (venlafexine) in depressed outpatients.

  1988cited by this paper
• Primary, secondary, and tertiary metabolite kinetics

  1988cited by this paper
• An ascending single-dose tolerance study of WY-45,030, a bicyclic antidepressant, in healthy men

  1987cited by this paper
• Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative.

  1986cited by this paper
• The relationship between serum concentrations and central nervous system actions of metoprolol.

  1985cited by this paper
• DMI, Wy-45,030, Wy-45,881 and ciramadol inhibit locus coeruleus neuronal activity.

  1985cited by this paper
• Drug metabolism and disposition : considerations in clinical pharmacology

  1985cited by this paper
• Clinical Pharmacokinetics: Concepts and applications.

  1983cited by this paper
• Influence of pentobarbital on effect and plasma levels of alprenolol and 4‐hydroxy‐alprenolol

  1979cited by this paper
• Fitting straight lines when both variables are subject to error.

  1978cited by this paper
• Commentary: a physiological approach to hepatic drug clearance.

  1975cited by this paper
• A physiological approach to hepatic drug clearance

  1975cited by this paper
• Clearance concepts in pharmacokinetics

  1973cited by this paper

• Successful multimodal treatment of venlafaxine overdose-induced catecholamine-refractory shock: a case report.

  2025cites this paper
• PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug–drug interactions with clarithromycin and paroxetine

  2024cites this paper
• FDA-approved drugs containing dimethylamine pharmacophore: a review of the last 50 years

  2024cites this paper
• Pharmacokinetic Bioequivalence and Safety Assessment of Two Venlafaxine Hydrochloride Extended-Release Capsules in Healthy Chinese Subjects Under Fed Conditions: A Randomized, Open-Label, Single-Dose, Crossover Study

  2024cites this paper
• CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with Depression

  2024cites this paper
• A fatal case of desvenlafaxine and paroxetine poisoning.

  2024cites this paper
• Carbamazepine, venlafaxine, tramadol, and their main metabolites: Toxicological effects on zebrafish embryos and larvae.

  2023cites this paper
• Precision dosing of venlafaxine during pregnancy: a pharmacokinetics modelling approach.

  2023cites this paper
• Efficacy and tolerability of desvenlafaxine in the real-world treatment of patients with major depression: a narrative review and an expert opinion paper

  2023cites this paper
• Pharmacogenetics in the Treatment of Huntington’s Disease: Review and Future Perspectives

  2023cites this paper
• Life-Threatening Cardiogenic Shock Related to Venlafaxine Poisoning—A Case Report with Metabolomic Approach

  2023cites this paper
• Lactational exposure to venlafaxine provokes late repercussions on reproductive parameters in male rat offspring

  2022influential citation
• Multiple-reaction monitoring (MRM) LC–MS/MS quantitation of venlafaxine and its O-desmethyl metabolite for a preclinical pharmacokinetic study in rabbits

  2022cites this paper
• Fabrication and characterization of electrospun nanofibers using biocompatible polymers for the sustained release of venlafaxine

  2022cites this paper
• All-Solid State Potentiometric Sensors for Desvenlafaxine Detection Using Biomimetic Imprinted Polymers as Recognition Receptors

  2022influential citation
• Joint population pharmacokinetic modeling of venlafaxine and O-desmethyl venlafaxine in healthy volunteers and patients to evaluate the impact of morbidity and concomitant medication

  2022influential citation
• Advances in Research at Synthesis Process Optimization and Quality Standard Improvement of O-desmethylvenlafaxine Succinate

  2022cites this paper
• Pluronic F-68 Montmorillonite As A Drug Delivery Vehicle For Extended Release Of Venlafaxine Hydrochloride

  2022cites this paper
• A narrative review of the importance of pharmacokinetics and drug–drug interactions of preventive therapies in migraine management

  2021cites this paper
• Pharmacogenomics in Pain Management: A Review of Relevant Gene-Drug Associations and Clinical Considerations

  2021cites this paper
• Presence of medicinal materials in drinking water: A review

  2021cites this paper
• Efficacy, Safety, and Tolerability of Ansofaxine (LY03005) Extended-Release Tablet for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Clinical Trial

  2021cites this paper
• Tandem Mass Spectrometry (MS/MS) in the Preclinical Pharmacokinetic Study of a Highly Prescribed SNRI Drug for Depression and Its Application to Oral Extended Release Solid Dosage Formulations in Rabbits

  2021cites this paper
• CYP2D6*10 polymorphism and the enantioselective O‐desmethylation of S‐(+)‐ and R‐(‐)‐venlafaxine in Japanese psychiatric patients

  2021cites this paper
• Drug-Drug Interactions in Prostate Cancer Treatment.

  2020cites this paper
• Rapid, Precise and Affordable Estimation of Venlafaxine and Its Metabolites in Highly Polluted Effluent Waters: Proof-of-Concept for Methodology

  2020cites this paper
• Revisited: Therapeutic and toxic blood concentrations of more than 1100 drugs and other xenobiotics

  2020cites this paper
• Effects of CYP2D6 Genotypes on Venlafaxine Metabolism in Japanese Psychiatric Patients With Depression

  2020cites this paper
• The cellular and molecular basis of major depressive disorder: towards a unified model for understanding clinical depression

  2019cites this paper
• The effect of the antidepressant venlafaxine on gene expression of biotransformation enzymes in zebrafish (Danio rerio) embryos

  2019cites this paper
• Cytochrome P450-mediated inhibition of venlafaxine metabolism by trimipramine.

  2019cites this paper
• Serotonin and Norepinephrine Reuptake Inhibitors.

  2019cites this paper
• The combination of mirtazapine plus venlafaxine reduces immobility in the forced swim test and does not inhibit female sexual behavior.

  2019cites this paper
• Pharmacokinetic correlates of venlafaxine: associated adverse reactions

  2019cites this paper
• Pharmacokinetics of venlafaxine in treatment responders and non-responders: a retrospective analysis of a large naturalistic database

  2019cites this paper
• Antidepressants in breast milk; comparative analysis of excretion ratios

  2018cites this paper
• Capillary electrophoresis in the enantioseparation of modern antidepressants: An overview.

  2018cites this paper
• Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine

  2018cites this paper
• Sex and body weight are major determinants of venlafaxine pharmacokinetics

  2018cites this paper
• Antidepressant polypharmacy and the potential of pharmacokinetic interactions: Doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism.

  2018cites this paper
• Reduced clearance of venlafaxine in a combined treatment with quetiapine

  2018cites this paper
• Impact of CYP2D6 on venlafaxine metabolism in Trinidadian patients with major depressive disorder.

  2018cites this paper
• Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

  2018cites this paper
• Efficient resolution of venlafaxine and mechanism study via X-ray crystallography.

  2018cites this paper
• Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study)

  2017cites this paper
• Carboxylate Salt Bridge‐Mediated Enamine Catalysis: Expanded Michael Reaction Substrate Scope and Facile Access to Antidepressant (R)‐Pristiq

  2017cites this paper
• Palpitations and Asthenia Associated with Venlafaxine in a CYP2D6 Poor Metabolizer and CYP2C19 Intermediate Metabolizer

  2017cites this paper
• Efficacy of Venlafaxine in Neuropathic Pain: A Narrative Review of Optimized Treatment.

  2017cites this paper
• Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

  2017cites this paper
• Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity

  2017cites this paper
• The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide.

  2017cites this paper
• Venlafaxine induced hepatotoxicity in a carcinoma of breast survivor with co-morbid depression

  2017cites this paper
• Enantioselective disposition of venlafaxine and its metabolite o-desmethylvenlafaxine in rats

  2017cites this paper
• Prediction of Plasma Concentration-time Profiles of Drugs in Humans from Animals Following Oral Administration: An Allometric Approach.

  2016cites this paper
• A novel prodrug strategy to improve the oral absorption of O-desmethylvenlafaxine.

  2016cites this paper
• Reversible cardiac dysfunction after venlafaxine overdose and possible influence of genotype and metabolism.

  2016cites this paper
• A Phenolic Ester of O-Desmethylvenlafaxine (ODV) Improves Uptake of ODV into the Brain

  2016cites this paper
• Interaction Between Risperidone, Venlafaxine, and Metronidazole: An Unknown Thread.

  2016cites this paper
• Differential inhibition of cardiac and neuronal Na(+) channels by the selective serotonin-norepinephrine reuptake inhibitors duloxetine and venlafaxine.

  2016influential citation
• Montmorillonite-alginate microspheres as a delivery vehicle for oral extended release of Venlafaxine hydrochloride

  2016cites this paper
• Pharmacokinetics of venlafaxine enantiomers and their metabolites in psoriasis patients

  2016cites this paper
• Olanzapine Long-Acting Injections After Neuroleptic Malignant Syndrome: Two Case Reports.

  2016cites this paper
• Stability indicating high performance thin layer chromatographic method for quantitation of venlafaxine in bulk and pharmaceutical dosage form

  2015cites this paper
• Development of an enantioselective assay for simultaneous separation of venlafaxine and O-desmethylvenlafaxine by micellar electrokinetic chromatography-tandem mass spectrometry: Application to the analysis of drug-drug interaction.

  2015cites this paper
• Desenvolvimento de uma fase extratora com polímeros de impressão molecular para extração em fase sólida de Venlafaxina, O-desmetilvenlafaxina e N-desmetilvenlafaxina em amostras de plasmas e análises por cromatografia líquida de ultra eficiência acoplada à espectometria de massas em tandem (UPLC-MS/

  2015cites this paper
• Novel antidepressant candidate RO-05 modulated glucocorticoid receptors activation and FKBP5 expression in chronic mild stress model in rats.

  2015cites this paper
• The pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog.

  2014cites this paper
• Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors

  2014cites this paper
• AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011.

  2014cites this paper
• PharmGKB summary: venlafaxine pathway

  2014cites this paper
• Distribution of Venlafaxine, O‐desmethylvenlafaxine, and O‐desmethylvenlafaxine to Venlafaxine Ratio in Postmortem Human Brain Tissue

  2014cites this paper
• Montmorillonite-PLGA nanocomposites as an oral extended drug delivery vehicle for venlafaxine hydrochloride

  2014cites this paper
• Depression: Psychiatrist is a Best Prescriber for an Antidepressant Medication

  2013cites this paper
• Phenolic Esters of O-Desmethylvenlafaxine with Improved Oral Bioavailability and Brain Uptake

  2013cites this paper
• Liquid chromatography tandem mass spectrometry method for the simultaneous stereoselective determination of venlafaxine and its major metabolite, O-desmethylvenlafaxine, in human plasma.

  2013cites this paper
• Sublingual methadone as an alternative to oral methadone for the treatment of breakthrough cancer pain.

  2013cites this paper
• A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine.

  2013cites this paper
• Pharmacokinetics of venlafaxine and its major metabolite o-desmethylvenlafaxine in freely moving mice using automated dosing/sampling system

  2012cites this paper
• Sustained release of venlafaxine from venlafaxine–montmorillonite–polyvinylpyrrolidone composites

  2011cites this paper
• AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011

  2011cites this paper
• Antidepressant Treatment of Geriatric Depression

  2011cites this paper
• Bioequivalence of venlafaxine modified-release capsule revisited with an innovative approach using experimental and predictive models.

  2011cites this paper
• Relative bioavailability of two formulations of venlafaxine extended-release 75-mg capsules in healthy brazilian male volunteers: A single-dose, randomized-sequence, open-label, two-period crossover study in the fasting and fed states.

  2010cites this paper
• Investigations on plant extracts for transdermal delivery of Repaglinide

  2010cites this paper
• Prediction of human drug clearance from two species: a comparison of several allometric methods.

  2010cites this paper
• Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes–focus on venlafaxine and O-desmethylvenlafaxine

  2010influential citation
• Serum Concentrations of Antidepressant Drugs in a Naturalistic Setting: Compilation Based on a Large Therapeutic Drug Monitoring Database

  2009cites this paper
• Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder.

  2009cites this paper
• Nouveau {4-[2-(diméthylamino)-1-(1-hydroxycyclohexyle)éthyle]phénoxy}phosphate ou sel correspondant pharmaceutiquement acceptable, procédé de production correspondant et composition pharmaceutique destinée à prévenir et traiter des troubles du système nerveux central et contenant ce composant à titr

  2009cites this paper
• Review of Duloxetine and Venlafaxine in Depression

  2009cites this paper
• Rapid and reliable genotyping procedure for detection of alleles with mutations, deletion, or/and duplication of the CYP2D6 gene.

  2009cites this paper
• Role of fixed coefficients and exponents in the prediction of human drug clearance: how accurate are the predictions from one or two species?

  2009cites this paper
• Preparation and Characterization of Venlafaxine Hydrochloride-Loaded Chitosan Nanoparticles and In Vitro Release of Drug

  2009cites this paper
• Venlafaxine Metabolism as a Marker of Cytochrome P450 Enzyme 2D6 Metabolizer Status

  2009cites this paper
• EFFECTS OF CYTOCHROME P450 ENZYME INHIBITORS ON THE PHARMACOKINETICS OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND VENLAFAXINE

  2008cites this paper
• Desvenlafaxine succinate for major depressive disorder.

  2008cites this paper
• A fatal case of venlafaxine overdose

  2008cites this paper
• Pharmacokinetic/Pharmacodynamic Modelling of Venlafaxine

  2008cites this paper
• Wirkstoffkonzentrationsbestimmungen zur Therapieleitung

  2008cites this paper
• Desvenlafaxine succinate for the treatment of major depressive disorder

  2008cites this paper